Virus News and Research

Latest Virus News and Research

Scientists explain how smallpox viruses disrupt immune systems

A team of researchers working in a high containment laboratory at the Centers for Disease Control and Prevention in Atlanta, GA, have solved a fundamental mystery about smallpox that has puzzled scientists long after the natural disease was eradicated by vaccination.: they know how it kills us.

23 Dec 2009

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.

23 Dec 2009

Cervical cancer more common among poorer women than more affluent women, say scientists

One of the reasons why cervical cancer is more common among poorer women could be because they start having sex at a younger age than more affluent women, scientists have said.

23 Dec 2009

Cell Medica receives second grant for development of adenovirus infection therapy

Cell Medica, a clinical stage cellular therapeutics company engaged in the development and delivery of cellular immunotherapy treatment strategies for infectious disease and cancer, has announced that is has appointed four key staff to drive forwards the Company’s activities in the commercialisation of cell therapy treatments.

22 Dec 2009

Select CVS/pharmacy locations and all MinuteClinic medical clinics offer H1N1 vaccinations

Select CVS/pharmacy locations and all MinuteClinic medical clinics throughout Arizona are now offering H1N1 vaccinations. H1N1 vaccine is now also available at select MinuteClinic locations in Illinois in the Chicago area and in Nevada in the Las Vegas area on demand seven days a week with no appointment necessary.

22 Dec 2009

Heart transplant patients face increased risk for skin cancers

Many heart transplant patients develop multiple skin cancers, with increased risk for some skin cancers among patients with other cancers and with increasing age, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

New findings reveal POPG lipid can prevent RSV infection in lungs

Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established. RSV is the major cause of hospitalization for children in the first two years of life, and is increasingly recognized as a dangerous pathogen in adults with chronic lung diseases, the elderly, and immunocompromised individuals. Currently, there is no effective vaccine for the virus.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

One dose of vaccine may be effective to protect infants and children from H1N1 virus, shows study

One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal.

21 Dec 2009

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

Second wave of H1N1 virus infection in the U.S. comes to an end

Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ago may be coming to an end, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.

19 Dec 2009

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

19 Dec 2009

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

MinuteClinic medical clinics in select CVS/pharmacy stores throughout Maryland, North Carolina and Tennessee are now offering H1N1 vaccinations on demand seven days a week with no appointment necessary.

19 Dec 2009

Opinion: Uganda anti-gay bill; Shah confirmation

Columnist Michael Gerson in a Washington Post opinion piece writes of Uganda's Anti-Homosexuality Bill of 2009 being considered by the country's parliament "that would impose new and harsher penalties on homosexuality, including life imprisonment and capital punishment. It also would force pastors and others to report homosexuals to the authorities.

18 Dec 2009

U.S. health officials announce shift in focus of prep trial in Botswana

U.S. health officials on Thursday announced they will shift the focus of a clinical trial in Botswana aimed at testing pre-exposure prophylaxis (PrEP) - the strategy that "a daily low dose of the drugs, which interfere with the ability of the virus to replicate, could also lower the risk of infection" - after researchers discovered they would be unable to determine the efficacy of Truvada, the medicine used in the trial, Reuters reports.

18 Dec 2009

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Cangene Corporation today reports that it has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use ("CHMP") regarding the immunoprophylaxis indication of Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin).

18 Dec 2009

Virus News and Research

Latest Virus News and Research

Scientists explain how smallpox viruses disrupt immune systems

Viron Therapeutics' three drug candidates granted U.S. patents

Cervical cancer more common among poorer women than more affluent women, say scientists

Cell Medica receives second grant for development of adenovirus infection therapy

Select CVS/pharmacy locations and all MinuteClinic medical clinics offer H1N1 vaccinations

Heart transplant patients face increased risk for skin cancers

New findings reveal POPG lipid can prevent RSV infection in lungs

Findings may help develop new antiviral drugs for influenza

One dose of vaccine may be effective to protect infants and children from H1N1 virus, shows study

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

TessArae's RM-Flu test granted FDA EUA

Swedish agency approves Medivir's Xerclear for treatment of cold sores

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Second wave of H1N1 virus infection in the U.S. comes to an end

SCCA's infection control program leads to suppression of potential H1N1 pandemic

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

Opinion: Uganda anti-gay bill; Shah confirmation

U.S. health officials announce shift in focus of prep trial in Botswana

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in